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Introduction
Atrial fibrillation (AF) is a very common arrhythmia with in-
creasing incidence and disease burden[1,2]. Rhythm control strategies 
are manifold varying from electrical cardioversion, anti-arrhythmic 
pharmacologic therapy, catheter (endocardial) ablation (CA), surgical 
AF (epicardial) ablation, and hybrid approaches[2]. Self eased diag-
nosis and patient empowerment will lead to a significant increase in 
AF diagnosis and awareness[3]. Since the development of the Maze 
procedure by James Cox in 1982 the role of surgical ablation has 
become more and more important in the treatment of atrial fibril-
lation (AF)[4]. As such concomitant surgical ablation of AF at the 
time of mitral valve surgery has a class Ia indication in the most 
recent guidelines[2]. Recently catheter based pulmonary vein isola-
tion has established itself as the first line of invasive therapy to treat 
paroxysmal AF[2]. However, it is apparent that some patients with 
paroxysmal AF fare less well than others. Certain risk factors for 
worse outcome are well known, such as duration of atrial fibrillation, 
extent of left atrial dilatation and left atrial fibrosis. Results of cath-
eter ablation for the persistent forms of AF remain suboptimal[5]. It 
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is established that in the setting of non-paroxysmal AF pulmonary 
vein isolation is not sufficient[6] and this is why more extensive le-
sions obtained with an epicardial approach may provide more dura-
ble results as the LAA is also targeted [7] during this procedure[2,8,9]. 
And finally the latest guidelines recommend the creation of AF 
HeartTeams to pose the indication for complex ablations[8]. In our 
clinic we applied the HeartTeam approach from our TAVI practice 
to the field of complex AF ablations and report our results herein.
Material and Methods 
This is a prospective registry approved by the local institutional 
review board. All patients included in this study provided an informed 
consent prior to surgery.
Patient selection   
The Atrial Fibrillation Heart Team Program began in 2013 and 
since then a total of 69 patients have been evaluated for an ablation 
procedure. Referrals for AF ablation were accepted from primary care 
doctors, cardiologists and from within our clinic. Self-referrals from 
patients directly were also accepted after screening of their medical 
history. Patients with paroxysmal AF and no additional risk factors 
or not requiring discontinuation of anticoagulation were triaged to 
catheter ablation as a first line of therapy. All other patients were 
considered for the endoscopic procedure. Most common inclusion 
criteria were: failed catheter ablation, or not suitable for such and 
patients with contraindication to anticoagulation. We did also 
take into consideration patient’s choice for such a procedure after 
informed consent about both therapies. Contraindications for the 
endoscopic procedure were previous cardiac or thoracic surgery, 
severely impaired pulmonary capacity and/or contraindication for 
endotracheal intubation and poor mobility.
AF HeartTeam 
Our institutional AF HeartTeam is an interdisciplinary team 
composed of several specialists who have no competing financial 
interest in the treatment of any given patient, identical to the TAVI 
board. Specialists composing this AF HeartTeam are: non invasive 
Cardiologist, interventional cardiologists, electrophysiology/device 
specialist, cardiac surgeon with AF experience and a nurse involved 
in patient care. All patients are discussed after a first consultation and 
prior to them receiving an appointment for any procedure. [Figure 1] 
depicts patient flow.
Preoperative Workup
Preoperative workup is composed of pulmonary function testing, 
9-day/Holter/ECG, cardiac CT to assess anatomy of the left atrium 
and the LAA. All patients had echocardiographic evaluation. The 
presence of significant risk factors for coronary artery disease, or a 
high calcium score on cardiac CT, mandated diagnostic coronary 
angiography.
Surgical Procedure
Surgery was performed by two dedicated AF surgeons (SPS 
and WJvB). The patient was prepared in suppine position with the 
patient draped for a median sternotomy. Cardio pulmonary bypass 
was always on standby. Double lumen endotracheal tube, central 
venous line and arterial line were used in all. All patients underwent 
intraoperative transesophageal echocardiography (TEE) to assess the 
left atrial appendage in particular by a cardiologist. The procedure, 
has previously been described[10], it is begun on the right side with the 
insertion of 3 ports, one 5mm and two 12mm Ports. CO2 insufflation 
is used to displace the mediastinum and lung. The pericardium is 
opened 1cm dorsally to the phrenic and 2 stay sutures are applied. In 
cases of prior ablation the bipolar pen is used in the sensing mode 
(Isolator Transpolar Pen™, Atricure, Westchester (OH), USA) to 
assess entrance and exit block over the pulmonary veins. After which 
the oblique and transverse sinus are opened. The transverse sinus is 
then dissected all the way to the left atrial appendage (LAA). With 
the GlidePath™ Dissector (Atricure, Westchester (OH), USA) 
the right pulmonary veins are encircled and then ablated with the 
bipolar radiofrequency clamp (Isolator Synergy Clamp™, Atricure, 
Westchester (OH), USA). Energy application was done (7-16 
Applications) several times until the tissue impedance as measured on 
the ablation console dropped in under 5 seconds. Once the ablation 
procedure complete entrance and exit block were confirmed with 
the bipolar pen (Isolator Transpolar Pen™, Atricure, Westchester 
(OH), USA) in pacing/sensing mode, the pericardium was closed, 
chest tube were inserted and the procedure repeated on the left 
side in the same manner. In all patients a connection from the left 
superior pulmonary vein to the base of the LAA was also done with 
the bipolar pen prior to addressing the left atrial appendage. Finally 
the left atrial appendage was addressed in all. The first 20 patients 
underwent left atrial appendage resection with a stapler (Endo 
GIA™ Reinforced Reload with Tri-Staple™, Medtronic, Mineapolis 
(MN), USA). After this we used the Atriclip Pro2 Device (Atricure, 
Westchester (OH), USA) which can be inserted through a port. The 
Stapler and Atriclip were only deployed when adequate closure was 
documented on TEE with a stump less than 1.0cm in all. A chest 
tube was inserted on the left side. The patients were extubated in 
the Operating Room and transferred thereafter. [Figure 2] depicts 
a schematic of the used lesion set in the patients. We assessed all 
LAA prior to incision to screen for LAA Thrombi. LAA closure 
was confirmed by Transesophageal echocardiography (TEE) in all 
patients.Figure 1: Patient flow directed by the AF Heart team
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Postoperative Management   
Postoperative management was conducted on an individual level, 
with increased experience by the entire team the threshold to no 
longer transfer patients from the operating room to the intensive care 
unit (ICU) decreased. Either in the ICU or the wake-up ward, the 
chest drains were removed rapidly (2h postoperatively) followed by 
a chest x-ray. Transfer to the regular ward with telemetry was then 
done. Patients were ambulating on the day of surgery. Anticoagulation 
management was tailored individually. Patients with Coumadin were 
kept on an INR 2-3 and Coumadin was not discontinued. Patient 
not on anticoagulation were given only sub-cutaneous low molecular 
weight heparin 6h postoperatively and then anticoagulated for 6 
weeks. Patients on NOAC where discontinued according to our 
institutional policy and guidelines. Postoperatively on Day one 
LMWH was given and on day 2 NOAC was reinstated for 6 weeks.
 
Antiarrhythmic medications were only given when severe 
arrhythmias were present postoperatively. In cases where 
hemodynamic compromise was severe; readmission to the ICU with 
IV Amiodarone and/or DC electroconversion was instituted.
Follow-up
Long-term rhythm follow-up was obtained in all patients (100% 
Complete). As per clinical standard all patients were seen by the 
referring cardiologists (or at our clinic) after 3, 12, 24 and 36 months. 
Clinical evaluation, echocardiography and Holter and/or 9 Day 
EKG (Bodyguardian, Preventice)  were performed either at our clinic 
(9day Holter) or by the referring cardiologists (24h Holter). During 
follow-up if the patient had an AF recurrence antiarrhythmics were 
started and a DC electroconversion was organized. If this failed a re-
Figure 2: Schematic description of the lesion set used during the TT procedure.
Figure 3: Rhythm outcomes.
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procedure because the LAA is managed. All patients were highly 
symptomatic and/or had intolerance to antiarrhythmic medications. 
In addition patient’s choice played an important part in decision-
making. [Table 2 ] shows Atrial Fibrillation characteristics.
 
Operative details
All procedures were performed successfully. No mortality occurred 
in this series. Median duration of the procedure was 124 minutes 
(Range 83-211). Pulmonary vein isolation was successful in 41 
patients (98%). In one patient a bleeding occurred during lumitip 
encirclement of the left pulmonary veins. The procedure was aborted 
and the patient came back after 3 months for a redo thoracoscopic 
pulmonary vein isolation on the left side – this time successful. All 42 
patients (100%) received a connecting line to the left atrial appendage. 
LAA closure was successful and complete 40 patients, while one 1 
patient had an insufficient LAA closure due to technical problems 
during application and in one patient with severe adherences LAA 
amputation with the stapler was not attempted.
ablation by catheter was discussed with the patient and the referring 
cardiologist.
Results are reported according to the Guidelines for reporting data 
and outcomes for the surgical treatment of atrial fibrillation[11].
Results
Patient selection  
Out of 69 patients evaluated, a total of 42 patients (Median 
CHA2DS2-VASC=3 (1-6), HAS-BLED=2 (1-6)) were treated (15 
paroxysmal AF, 27 non-paroxysmal AF). [Table 1] depicts general 
patient’s demographics ablated in this series. The 2017 HRS/EHRA/
ECAS/APHRS/SOLAECE Expert Consensus Statement on 
Catheter and Surgical Ablation of Atrial Fibrillation[9] and the 2016 
ESC Guidelines for the management of atrial fibrillation developed 
in collaboration with EACTS[8] where applied for patient selection. 
A total of 5 patients (12%) with paroxysmal AF and no prior catheter 
ablation were included after discussion in the AF HeartTeam.
A subset of 17 patients despite paroxysmal AF were not deemed 
suitable for catheter ablation by the AF HeartTeam and addressed 
for catheter ablation at our institution. Reason for this was mainly 
patient choice as these patients presented already with the desire 
not to undergo catheter ablation. The second reason was the ability 
to discontinue oral anticoagulation after the thoracoscopic ablation 
Table 2: Preoperative Atrial Fibrillation
 Paroxysmal (n=15) non Paroxysmal (n=27)
Duration
(years)
3.7 ± 3.5 4.4 ± 4.6
no Ablation 15 (33%) 7 (26%)
CA 1 5 (33%) 10 (37%)
CA 2 6 (40%) 8 (30%)
CA 3+ 4 (27%) 2 (7%)
CA=Catheter Ablations
Table 3: Postoperative Outcomes
 Outcomes Perioperative Follow-up
Sternotomy 2 0
Bleeding* 2 0
Intubation > 6h 1 0
Stroke/TIA 0 0
Pacemaker 0 1
MACCE 1 0
Pleural Effusion 2 7 (16%)
Pleurodhesis 0 1
Death 0 0
MACCE=Major Adverse Cardiac and Cerebrovascular Event
Table 4: Rhythm Outcomes
 Paroxysmal 
(n=15)
Non Paroxysmal
(n=27)
Freedom from AF 
off AAD 
93% 89%
Follow-up (months) 
Median(range)
15 
(11-43)
16  
(11-43)
DC Electroconversion (during Blanking 
P.)
5 10 (37%)
re-Ablation - Right 0 1
re-Ablation – Left + Right 1 4
NOAC during FU 1 4 (15%)
AAD=Antiarrhythmic Drugs
Table 1: Patient Demographics
n= 42
Age (y) 65 +/- 7
Gender (M) 14 (54%)
HTN 32 (76%)
DM 13 (31%)
CAD 12 (29%)
Stroke/TIA 4 (10%)
CHF 6 (19%)
CHA2DS2-VASc median 2 (R: 0-4)
LVEF (%) 60 (40-77)
LA Diameter (mm) 48+/-10
LAVI (ml/m2) 34+/-6
Medications:
Beta-Blocker 26 (62%)
Ca-Antagonists 7 (21%)
Cordarone 9 (23%)
Marcoumar 14 (33%)
NOAC 24 (57%)
no Anticoag 4 (10%)
Aspirin 10 (38%)
Paroxysmal AF 15/42
Non Paroxysmal AF 27/42
mean +/- stdv
LVEF=Left Ventricular Ejection Fraction, LA=Left Atrium, LAVI=Left Atrium Volume Index
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the right inferior pulmonary vein. In addition left sided substrate 
modification and a right sided cavo-tricuspid-isthmus line were 
performed. Only one patient with paroxysmal AF remained under 
oral anticoagulants due to an incomplete LAA closure with a 
CHADSVASC score of 3.
In the non-paroxysmal group overall 5 patients (12%) required a 
redo procedure. This was due to pulmonary vein reconnection and 
mitral isthmus flutter. Despite optimal LAA closure 15% of patients 
remained under oral anticoagulation with NOACS.
Discussion
   This is the first study that highlights the role of an AF HeartTeam 
Program (AFHTP) in appropriately utilizing both catheter and 
minimally invasive surgical ablations in the management of AF. Our 
study shows that AFHTP can yield excellent patient outcomes for 
patients with improved communication between cardiologists and 
cardiac surgeons.
  Too often, surgeons and electrophysiologists work in silos taking 
care of the same problem. With increased communication between 
specialists and increased awareness about quality and outcomes the 
surgical community has slowly begun to embraces the HeartTeam 
as it has become evident from the TAVI HeartTeams and team 
assessment of coronary artery disease.
  The results for the surgical approach when randomized to either 
catheter or totally thoracoscopic ablation demonstrated a high rate of 
freedom of AF at 12 months, 77 vs. 42% in favor of the thoracoscopic 
procedure[12]. Other studies have shown a 2-year success rate of 
70–80% for preventing AF recurrence in these complex patients[13]. 
Furthermore the relatively high complication rate initially described 
in the FAST trial[12] was demonstrated to become significantly lower 
in a very recent report by Vos et al.[14]. Over a period of 11 years in a 
dedicated AF center n=558 patients underwent thorascopic ablations, 
the freedom from complications was 89% and 97% for complications 
with life-long affecting consequences[15].
  We believe that the surgical procedure comes with some advantages 
which are: bipolar RF as energy source, large antral epicardial 
bites isolation, inclusion of the entire epicardial fat pads and the 
ganglia within the wide antral ablation, and most importantly 
electrical isolation the LAA by amputation. The importance of this 
is confirmed by interesting EP data on targeting the LAA during 
first time catheter ablation[16]. As we have demonstrated, the Atriclip 
exclusion of the LAA leads to it’s electrical silencing[17].
 The most recent guidelines ESC suggest that a dedicated AF 
Heartteam setting and integrated AF care chain may be crucial for 
good outcomes[8]. Our’s is the first report of such an integrated care 
chain.
  Anticoagulation management after ablation procedures is directed 
by the guidelines[8]. However LAA closure plays a crucial role in 
this setting, as this is done as an add-on to the ablation procedure. 
Though the interventional cardiology literature suggests that we can 
discontinue anticoagulation when the LAA is closed[18], after ablation 
All but one patient were extubated in the Operating theatre. One 
patient showed prolonged effect of sedatives and was extubated 5h 
postoperatively and discharged to the regular ward the next day.
The first 20 patients spent the first night in the intensive care 
unit (ICU) thereafter all patients were individually assessed for 
the intensive care unit or just to transit through the wake-up ward. 
Median duration of stay in the ICU and Recovery-Ward was 18h 
(Range 2-72) and 4h (Range 3-48). Chest-tubes were removed 
shortly after arrival in the intensive care unit /wakeup ward, after 
chest X-ray Patients were transferred to the regular ward on the 
same day in some, or on postoperative day one. A summary of the 
postoperative Outcomes is depicted in [Table 3].
Complications
Conversion to a sternotomy was necessary in 2 patients. In one 
case it was due to bleeding from a tear in the right upper pulmonary 
vein during encircling with the dissector. In the second case this 
occurred in a patient with severe scoliosis while inserting the bipolar 
clamp. Both cases were managed without cardiopulmonary bypass 
and had an uneventful postoperative course leaving the hospital after 
5 and 8 days in sinus Rhythm. In one patient a bleeding occurred 
during encircling of the left pulmonary veins. In a second patient 
on postoperative day 1 a hematothorax occurred which required 
placement of a drain. One patient suffered ECG changes on the 
regular ward on postoperative day 1. Emergency PCI was performed 
on a LAD occlusion. Pleural effusions was a “common” postoperative 
problem. Effusion was managed conservatively with diuretics. When 
the chest X-rax prior to discharge demonstrated effusion a pleural 
ultrasound was performed for quantitative evaluation. In patients 
with >500ml a thoracentesis was performed. In one patient who 
developed chronic pleural effusions, which did not disappear despite 
pharmacologic management and several thoracentesis a pleurodhesis 
was necessary 18months out.
Cardiac Rhythm Outcomes   
During the early postoperative period Direct-Current (DC) 
cardioversion was aggressively performed in all patients, when AF 
recurrence was symptomatic or a hemodynamically relevant. This 
occurred in 13 patients once, in 1 Patient three times and in 1 patient 
four times. After DC Conversion pharmacologic treatment with 
Amiodarone and/or Betablockers was started. Overall 9 Patients 
(21%) required antiarrhythmic medication after hospital discharge 
for atrial arrhythmias. A total of 6 patients (14%) required a redo 
procedure for AF recurrence. [Table 4] shows Rhythm status at 
Follow-up.
Follow-up
Median follow-up was 20 Months (11-43). During follow-up no 
mortality, thromboembolic events, TIA or stroke occurred. Overall 
(12 month) freedom from AF and antiarrhythmic medication 
was 93% and 89% for paroxysmal and non-paroxysmal patients 
respectively.
In the paroxysmal AF group, one patient had a symptomatic atrial 
arrhythmia recurrence after 18 month, which required a catheter 
ablation. This was due to a peri-mitral flutter and a reconnection of 
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